Neuralink co-founder Max Hodak's Science Corp, which offers a retinal implant for age-related macular degeneration, raised $400M at a $3.5B valuation
First reported by Bloomberg ·
The cost to access early-stage neurotech with demonstrated European market entry drops significantly.
Science Corporation, a medical technology startup founded by former Neuralink president Max Hodak, has secured $400 million in Series D funding, valuing the company at $3.5 billion. The new funding round was led by Khosla Ventures and included participation from the Ackman Oxman Institute, Tenet Healthcare, 885 Capital, Y Combinator, and PLC Neurotech. Science Corporation's primary product is PRIMA, an implantable chip designed to restore vision for individuals suffering from age-related macular degeneration. The device has already received approval in Europe and is currently undergoing trials for other vision-impairing conditions. The company announced that it is also testing PRIMA for Stargardt's disease, another condition that causes blindness. With this substantial investment, Science Corporation intends to pursue FDA approval for PRIMA in the United States through the Humanitarian Device Exemption pathway, targeting rare conditions. Furthermore, the company is developing a bio-hybrid sensor for direct brain connection, with initial human trials planned for conditions like Parkinson's disease and other brain injuries.
This funding round propels Science Corporation's valuation to $3.5 billion, signaling strong investor confidence in the potential of advanced neurotechnology for vision restoration and broader neurological applications. The company's dual focus on an immediately applicable product for macular degeneration, coupled with its long-term ambition for direct brain interfacing, positions it as a key player in the burgeoning brain-tech market. The expansion into the US market via the FDA's Humanitarian Device Exemption indicates a strategic approach to navigating regulatory landscapes for innovative medical devices.
The significant investment and high valuation suggest a growing market appetite for technologies that directly address debilitating neurological conditions, moving beyond theoretical concepts to tangible treatments. This success could spur further investment in similar ventures, potentially accelerating the development and adoption of brain-computer interfaces and advanced retinal prosthetics. Investors are betting on the convergence of AI, biotechnology, and advanced hardware to create next-generation therapeutic solutions.
AI-written summary. May contain errors.